Trending...
- Proto-Punk Legends The Dictators Release First New Studio Album In 23 Years
- Agenda Announced for Creative Tech New York 2024
- Lions Gate Entertainment Corporation (LGF.A; LGF.B) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
LOS ANGELES, Sept. 5, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a corporate presentation at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held in New York from September 9-11, 2024.
Armata's presentation is scheduled for Wednesday, September 11, from 8:00-8:30 AM ET.
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
More on Nyenta.com
Media Contacts:
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
[email protected]
310-665-2928 x234
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
[email protected]
212-915-2569
SOURCE Armata Pharmaceuticals, Inc.
Armata's presentation is scheduled for Wednesday, September 11, from 8:00-8:30 AM ET.
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
More on Nyenta.com
- New Rochelle: Senior Lunch at Hudson Park
- New Rochelle: Arrangements for Hon. Leonard C. Paduano
- "Monotheism and Devils" is the theologically dedicated sequel of "Prince of Eurasia" of the Islamic cleric and executive producer Prince Oak Oakleyski
- Diisocyanates and Polyisocyanates Market to Grow by USD 13.01 Billion (2024-2028) with AI-Powered Insights, Construction Boom to Drive Revenue - Technavio
- Lumilore: The Original Story of the Dragon Who Glowed by Sabine Ruh House
Media Contacts:
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
[email protected]
310-665-2928 x234
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
[email protected]
212-915-2569
SOURCE Armata Pharmaceuticals, Inc.
Filed Under: Business
0 Comments
Latest on Nyenta.com
- Dollar Falls, Gold Near Record as Fed Rate Cut Speculation Grows
- Always The VIP Launches Promotional Dinner Parties at Fushimi in Times Square NYC
- Weekly Recap: 12 Health Press Releases You Might Have Missed
- TrustVare Releases PST to EML Converter: Flawless Email Conversion Made Simple
- Green Office Partner Ranked #1 on Crain's 2024 List of Best Places to Work in Chicago
- City of New Rochelle Hosts Outdoor Movie Night: "IF" on September 20th
- INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit
- Rochester: The International Plaza Market Sunday celebrates Hispanic Heritage Month and 3rd Annual International Salsa Day Celebration
- Demeter Fragrance Introduces "Oak": A Fragrance That Captures the Timeless Essence of Nature
- PORT AUTHORITY AND JFK MILLENNIUM PARTNERS ANNOUNCE THE INSTALLATION OF A NEW ART EXHIBIT BY RENOWNED BROOKLYN ARTIST RON BASS AT JOHN F. KENNEDY INTERNATIONAL AIRPORT'S TERMINAL 7
- Diversified Industrial Acquisition Agreement, Plus Major Contract Award for Large Fleet Trucking Provider: MingZhu Logistics: Stock Symbol: YGMZ
- Messageware Z-Day Guard v1.5 Expands MDR Security to Azure, Exchange, and Windows Servers
- Oh Polly takes on New York Fashion Week with Fashion PR Firm covering the event
- Rochester Public Market to Host 19th Annual Artist Row Sunday
- Rochester: West River Wall improvements project named APWA Public Works Project of the Year
- What is the Power of We Partners w/ Sakhi for South Asian Survivors to Combat Gender-Based Violence
- New York's JFK T6 to Set a New Standard for Travel Retail in North America in Partnership with Avolta Companies Hudson and Dufry
- Join The Flip Project to Make a Difference This Election
- European E-Signature Market Poised for Explosive Growth by 2030
- STMicroelectronics N.V. Class Action: The Gross Law Firm Reminds STMicroelectronics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 22, 2024 - STM